Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reproducible erythroid aplasia caused by mycophenolate mofetil.

K Arbeiter1, L Greenbaum, E Balzar

  • 1Department of Pediatrics, Vienna Medical School AKH Wien, Vienna, Austria.

Pediatric Nephrology (Berlin, Germany)
|February 7, 2001
PubMed
Summary

Mycophenolate mofetil (MMF) can cause erythroid aplasia, a severe anemia. This case study confirms a direct link between MMF and this serious side effect in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Criticism of the National Association of Dental Faculties.

The Dental register·2021
Same author

Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree - CORRIGENDUM.

The international journal of neuropsychopharmacology·2019
Same author

Neural mechanisms underlying stress resilience in Ahi1 knockout mice: relevance to neuropsychiatric disorders.

Molecular psychiatry·2013
Same author

GSK-3β inhibition protects mesothelial cells during experimental peritoneal dialysis through upregulation of the heat shock response.

Cell stress & chaperones·2013
Same author

Contribution of genetic variants to pain susceptibility in Parkinson disease.

European journal of pain (London, England)·2012
Same author

Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.

The pharmacogenomics journal·2011

Area of Science:

  • Hematology
  • Immunosuppressive therapy
  • Transplantation

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressant used in transplantation.
  • Anemia has been anecdotally linked to MMF, but direct causality was unproven.
  • Erythroid aplasia is a rare condition characterized by the cessation of red blood cell production.

Observation:

  • A patient with chronic graft failure developed erythroid aplasia while on MMF immunosuppression.
  • The patient's condition resolved upon discontinuation of MMF.
  • Erythroid aplasia recurred when MMF was reintroduced, establishing a clear temporal relationship.

Findings:

  • This case provides definitive evidence of a causal relationship between MMF and erythroid aplasia.
  • Drug re-challenge confirmed MMF as the causative agent for the observed anemia.

Related Experiment Videos

  • MMF-induced erythroid aplasia is a significant, albeit rare, adverse effect.

    • Implications:

    • Clinicians should consider MMF as a potential cause of erythroid aplasia in transplant recipients.
    • Monitoring for anemia in patients receiving MMF is crucial.
    • This finding may influence immunosuppressive strategies in certain patient populations.